Hengyi Technology

Hengyi Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative drugs for metabolic, cardiovascular, and inflammatory diseases. Founded in 2018 by former executives from Hengrui Medicine, the company has built a robust pipeline through a combination of internal development and the acquisition of high-potential assets. Its lead candidate, SHR4640, is a highly potent URAT1 inhibitor currently in Phase 3 clinical trials for the treatment of gout and hyperuricemia. Additionally, the company is developing SHR1459, a BTK inhibitor for B-cell malignancies, and has involvement with the SGLT2 inhibitor Henagliflozin. Hengyi Biotech aims to address significant unmet medical needs in the Chinese market and beyond by leveraging its deep expertise in drug discovery and clinical development. The company is backed by top-tier global investors including Sequoia China, Qiming Venture Partners, and GIC.